Historical record - last NADAC effective date: 1/22/2014
Product Information
PACLITAXEL 300 MG/50 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $1.7700 per ML under NDC 63323076350. Its NADAC has been published 5 times since Jan 22, 2014.
FDA first approved this application on Nov 27, 2006. Its Orange Book therapeutic-equivalence code is AP.
Strength
6 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323076350
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
1/22/2014
Active Ingredients
PACLITAXELApproval Type
Generic (ANDA)
FDA Application
ANDA077574FDA Approved
11/27/2006
TE Code
AP
On Market Since
3/20/2009
Pharmacological Classes
Price Statistics
The NADAC for PACLITAXEL 300 MG/50 ML VIAL has been published 5 times since Jan 22, 2014, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7700 per ML |
|---|---|
| All-time high | $1.7700 (Feb 19, 2014) |
| All-time low | $1.7700 (Jan 22, 2014) |
| Median price | $1.7700 |
| Average price | $1.7700 |
| Largest weekly change | 0.0% (Jan 29, 2014) |
| Weeks tracked | 5 |
| Tracking since | Jan 22, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Feb 19, 2014 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Paclitaxel market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Microtubule Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PACLITAXEL 300 MG/50 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for PACLITAXEL 300 MG/50 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $1.7700 per ML (NDC 63323076350), effective Feb 19, 2014.
How has the price of PACLITAXEL 300 MG/50 ML VIAL changed over time?
Over the history we have for it, the NADAC for PACLITAXEL 300 MG/50 ML VIAL has held within roughly two percent of its current level. It has been tracked across 5 weekly CMS publications since Jan 22, 2014.
What are the highest and lowest recorded NADAC prices for PACLITAXEL 300 MG/50 ML VIAL?
Since Jan 22, 2014, the NADAC for PACLITAXEL 300 MG/50 ML VIAL has ranged from a low of $1.7700 (Jan 22, 2014) to a high of $1.7700 (Feb 19, 2014), with a median of $1.7700 per ML.
Are there cheaper alternatives to PACLITAXEL 300 MG/50 ML VIAL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PACLITAXEL 300 MG/50 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures PACLITAXEL 300 MG/50 ML VIAL?
PACLITAXEL 300 MG/50 ML VIAL (NDC 63323076350) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.